Key result
Maternal serum AFP ≥3 MOM detects ~79% of open neural tube or abdominal wall defects.
Why the study?
The efficiency of general AFP screening programs is considerably affected by the action limits used for diagnostic follow-up, and the potential benefit of differential action limits was analyzed.
Does the use of differential action limits for maternal serum AFP screening improve the efficiency of detecting fetal defects and obstetric risks in pregnant women?
Observational (n=18,037)
Does the use of differential action limits for maternal serum AFP screening improve the efficiency of detecting fetal defects and obstetric risks in pregnant women?
The use of differential action limits for maternal serum AFP screening can improve the efficiency of detecting specific fetal defects and obstetric risks.
Answers are grounded in this paper and cite their sources.
Elevated AFP flags most open defects in this cohort; leaves open whether differential thresholds improve screening efficiency.
The efficiency of a general AFP‐screening program is considerably affected by the action limit used for recommended diagnostic follow‐up procedures. We have analyzed if this efficiency could be enforced by the use of differential action limits for different purposes. A total of 18 037 pregnancies of known outcome were analyzed for their AFP‐levels in maternal serum (MS‐AFP) between the 15th and 17th gestational weeks. The individual AFP test results were expressed in multiples of the normal median value (MOM) for singleton pregnancies of the same gestational age. MS‐AFP levels ≤ 3 MOM were found in 22/28 pregnancies (78.6 per cent) affected by open neural tube‐ or abdominal wall defects, but only in 0.7 per cent of the 17 872 normal singleton pregnancies. Obstetric risk pregnancies, e.g. multiple pregnancies, impending abortions, and pregnancies eventually ending with perinatal deaths and children with low birth weight, were found to be overrepresented above the MS‐AFP level 1.8 MOM (the 94th percentile). The employment of differential action limits, i.e. at 3 MOM for further diagnostic attempts to eventually detect open neural tube‐ or abdominal wall defects, at 1.8 MOM for identification of certain obstetric risk pregnancies requiring close monitoring and below 0.25 MOM to reveal nonviable pregnancies to be terminated is likely to improve the efficiency of an AFP‐screeningprogram.
No takes yet. Share an insight, caveat, or question.
Schnittger et al. (1984) conducted an observational in Pregnancy (n=18,037). Maternal serum alpha-fetoprotein (MS-AFP) screening vs. Normal singleton pregnancies was evaluated on Proportion of pregnancies with MS-AFP levels of 3 MOM or higher. Maternal serum alpha-fetoprotein levels ≥3 MOM were found in 78.6% of pregnancies with open neural tube or abdominal wall defects, compared to 0.7% of normal singleton pregnancies.
Synapse has enriched 10 related papers. Consider them for comparative context: